Gefitinib

Pipeline Programs↗

Active Trials↗

Companies Involved↗

Gefitinib is an early-stage landscape with 0 programs across 1 company. The most active players are Hunan Kelun Pharmaceutical Co., Ltd..

Intelligence

Pipeline Metrics

Competitive Density

0/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

88/100

Attrition Rate

8/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved

Phase 3

Phase 2

Phase 1

Preclinical

Key Players

Top Companies

Hunan Kelun Pharmaceutical Co., Ltd.

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

clinical trials

Completed7 · 58%

Unknown status4 · 33%

Terminated1 · 8%

Clinical Trials

Trial Activity

12 trials

Pharmocokinetic/Pharmacodynamic (PK/PD) Study of the Combination Cetuximab/Gefitinib

Completed·HHarrison Clinical Research·Phase 1·NCT00820417·63 enrolled

Phase II Trial to Correlate Radiographic Response Induced By Gefitinib With Mutations in the Protein-Tyrosine Kinase Domain of the EGF Receptor Gene

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00588445·65 enrolled

Bioequivalence Study of Gefitinib Tablets Under Fed Conditions

Completed·HHunan Kelun Pharmaceutical Co., Ltd.·Phase 1·NCT03050177·38 enrolled

Selumetinib in Combination With Gefitinib in NSCLC Patients

Completed·NNational Taiwan University Hospital·Phase 1/2·NCT02025114·34 enrolled

A Phase I Study of Safety and Pharmacokinetics of Volitinib in Combination With Gefitinib in EGFR(+) NSCLC

Completed·HHutchison Medipharma Limited·Phase 1·NCT02374645·64 enrolled

Gefitinib Versus Pemetrexed for Previously Treated NSCLC Patients

Completed·GGachon University Gil Medical Center·Phase 2·NCT01783834·95 enrolled

Study With Gefitinib in Combination With Olaparib (AZD2281) Versus Gefitinib Alone

Completed·SSpanish Lung Cancer Group·Phase 1/2·NCT01513174·186 enrolled

Feasibility Study to Estimate Number of Patients With Precancerous Areas in Their Airways and the Response to Gefitinib

Terminated·PPapworth Hospital NHS Foundation Trust·Phase 2·NCT01405846·32 enrolled

First Line Gefitinib by FDG-PET Metabolic Response

Unknown status·—·Phase 2·NCT01510990·60 enrolled

Gefitinib Combined With Thalidomide to Treat NSCLC

Unknown status·—·Phase 2/3·NCT02387086·380 enrolled

Erlotinib 100mg qd Versus Gefitinib 250mg qd for EGFR Mutant Nsclc

Unknown status·SSun Yat-sen University·Phase 2·NCT01955421·224 enrolled

Second-Line Irinotecan or Gefitinib in Docetaxel Pretreated NSCLC

Unknown status·GGachon University Gil Medical Center·Phase 2·NCT00319800·50 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)